By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein
Controlling chronic ENT conditions with precise drug elution and long action
Lyra Therapeutics is a developer of therapies aimed at specific causes of ear, nose, and throat diseases. The treatments are drugs assisted by extended-release devices. Its two lead products in the development pipeline target chronic rhinosinusitis (CRS), a debilitating nasal inflammatory disease typically affecting millions of patients throughout their lifetimes, under different circumstances. One, coded LYR-210, is a long-acting anti-inflammatory (mometasone furoate) implanted in surgery-naïve patients, now in preparation for a Phase 3 trial. The other, LYR- 220, now completing preclinical development, delivers the same drug but with a device designed for post-surgery patients. Both products are based on the company’s XTreo platform, similar to drug-eluting stent technology combining a biocompatible mesh scaffold, engineered elastomeric matrix, and a polymer-drug complex.